Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Vinorelbine Injection USP 10mg/mL vial (Sagent)
Section 19A approved medicine
(Approval lapsed) Vinorelbine Injection USP 10mg/mL vial (Sagent)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 517
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
NAVELBINE vinorelbine 10mg/mL (as tartrate) injection vial - AUST R: 62246
Indication(s)
NAVELBINE is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. NAVELBINE is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.